- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Intra-Cellular Therapies (NASDAQ:ITCI), Quotes and News Summary
Intra-Cellular Therapies (NASDAQ: ITCI)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-08 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.920 | -0.780 | 0.1400 | ||||
| REV | 33.650M | 34.996M | 1.346M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Intra-Cellular Therapies Questions & Answers
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Roivant Sciences (NASDAQ:ROIV).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by UBS on Tuesday, June 14, 2022. The analyst firm set a price target for 75.00 expecting ITCI to rise to within 12 months (a possible 34.84% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $55.62 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.